Research Studies
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER
Details
Age
Adult
Type of Study
Treatment
Principal Investigator
David Camidge, MD, PhD
Study ID
Protocol Number: 21-3772
More information available at ClinicalTrials.gov: NCT04077099
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers